Edwards Lifesciences 1 Year or Less increased by 7.0% to $1.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 68.4%, from $704.90M to $1.19B.
Higher values indicate greater near-term liquidity and lower interest rate risk, while lower values suggest a longer-term investment strategy.
This metric measures the total amortized cost of debt securities available for sale that are scheduled to mature within...
Standard disclosure for bank investment portfolios to show maturity distribution.
other_available_for_sale_securities_debt_maturities_next_18dde9| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $213.40M | $204.80M | $305.00M | $255.20M | $372.40M | $358.20M | $440.40M | $425.80M | $417.00M | $291.90M | $719.20M | $704.90M | $744.70M | $1.11B | $1.19B |
| QoQ Change | — | -4.0% | +48.9% | -16.3% | +45.9% | -3.8% | +22.9% | -3.3% | -2.1% | -30.0% | +146.4% | -2.0% | +5.6% | +49.0% | +7.0% |
| YoY Change | — | — | — | +19.6% | +81.8% | +17.4% | +72.6% | +14.3% | +16.4% | -33.7% | +68.9% | +69.0% | +155.1% | +54.3% | +68.4% |